Plain-English translation of NCT07179770 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a medication called to see how it affects a specific protein (called CAIX) that appears on kidney cancer cells. Researchers will use special imaging scans before and 4 weeks after you start the medication to measure whether the treatment changes how much of this protein your tumors produce. Understanding these changes could help doctors develop better combination treatments in the future.
Many patients with advanced kidney cancer stop responding to standard immunotherapy treatments, and doctors need new strategies to help them. This study will show whether this medication might work better when combined with other therapies designed to target the CAIX protein on cancer cells.
You will start taking the medication and undergo a special imaging scan called a PET scan before treatment begins. Four weeks after starting the medication, you will return for another PET scan to see how the treatment has affected the tumor markers. The study involves approximately 12 patients total and will help researchers understand whether this medication might be combined with other treatments to fight kidney cancer more effectively.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States